Welcome to our dedicated page for Proqr Therapeuti news (Ticker: PRQR), a resource for investors and traders seeking the latest updates and insights on Proqr Therapeuti stock.
ProQR Therapeutics N.V. reports developments as a clinical-stage biopharmaceutical company built around its proprietary Axiomer™ RNA editing platform. The technology uses ADAR-mediated RNA editing to make single-nucleotide changes in RNA, with pipeline updates centered on AX-0810 and additional programs across rare and prevalent diseases with unmet need.
Recurring company news includes scientific conference presentations, investor and analyst events, clinical-program updates, development-candidate selections, AI-enabled discovery initiatives, and collaborations such as Ginkgo Bioworks and Eli Lilly. ProQR also reports annual operating and financial results, annual general meeting materials, board composition changes, and other governance matters tied to its Nasdaq-listed public-company profile.
ProQR (Nasdaq: PRQR) reported Q1 2026 results and a pipeline update. Cash and cash equivalents were €81.1 million, providing runway into mid-2027. Net loss was €13.4 million (€0.13 per diluted share).
Key milestones include AX-0810 Phase 1 target engagement data in Q2 2026, an IIT in pediatric biliary atresia with data in H1 2027, and CTA filings for AX-0811 in mid-2026 and AX-0422 in early 2027. The company also advanced its Axiomer RNA editing platform through AI-enabled discovery, a strategic partnership with Ginkgo Bioworks, and formation of an AI Advisory Board.
ProQR (Nasdaq: PRQR) will present multiple new data sets on its Axiomer™ RNA editing platform at major 2026 conferences, including TIDES USA, ASGCT, the RNA Society meeting, and EASL. Highlights cover liver and CNS programs, including AX-0422, AX-2402, AX-2911, and progress of lead program AX-0810 toward initial clinical data in healthy volunteers expected later this quarter.
ProQR (Nasdaq: PRQR) announced its Annual General Meeting of Shareholders will be held on June 2, 2026 at 15:00 CEST at Allen Overy Shearman Sterling LLP offices in Amsterdam. Relevant meeting documents, including the notice, agenda and explanatory notes, will be available on ProQR's investor website and on the SEC website.
Shareholders who wish to attend must register as described in the notice and agenda.
ProQR (Nasdaq: PRQR) announced the nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors on April 30, 2026. Dr. Hinsch Gylvin is Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim with more than 20 years of global drug development experience.
The nomination will be submitted for shareholder approval at ProQR’s upcoming Annual General Meeting; if appointed, she will serve as an independent non-executive director.
ProQR (Nasdaq: PRQR) outlined pipeline progress at its April 8, 2026 investor event, highlighting lead RNA editing program AX-0810, selection of biliary atresia for Phase 2, and multiple programs advancing toward clinic.
The company said AX-0810 target engagement data are on track for this quarter, AX-0811 CTA is expected mid-2026, and several clinical readouts are expected within a cash runway into mid-2027.
ProQR (Nasdaq: PRQR) announced an AI strategy for its Axiomer RNA editing platform, partnering with Ginkgo Bioworks and forming an AI Advisory Board. ProQR gains access to Ginkgo’s 50+ instrument autonomous lab, expects a CTA mid-2026 for its first AI-discovered candidate, and initial clinical data by year-end 2026.
The Advisory Board includes leaders from AI and techbio to guide discovery model development and best practices.
ProQR (Nasdaq: PRQR) will host a virtual Investor and Analyst Event on April 8, 2026 from 10:00 am ET covering its Axiomer™ RNA editing pipeline.
The company will highlight programs beyond AX-0810, announce new programs with upcoming clinical readouts, and unveil AX-0810's primary indication ahead of target engagement data expected in H1 2026.
ProQR (Nasdaq: PRQR) reported year-end 2025 results and a pipeline update. Key points: €92.4M cash at Dec 31, 2025, €52.8M net cash used in operations, €44.7M R&D spend, and a €42.2M net loss. Clinical progress includes AX-0810 Phase 1 dosing with target engagement data expected 1H 2026; Development Candidates selected for AX-2402 and AX-2911. The company achieved $4.5M in Eli Lilly collaboration milestones, supporting runway into mid-2027.
ProQR (Nasdaq: PRQR) announced management will present at the Citizens Life Sciences Conference on March 11, 2026 at 3:25pm ET. A live webcast and recording will be available via the company’s Investors & Media website events page. Archived webcasts will remain available for about 30 days.
ProQR (Nasdaq: PRQR) announced planned changes to its Board of Directors effective at its 2026 Annual General Meeting. Co-founder Dinko Valerio and director Alison Lawton will rotate off the Board as their terms conclude. An executive search firm has been engaged to identify new director candidates to support long-term value creation.
The Board says the changes reflect governance, succession planning, and support for advancing ProQR's clinical programs.